Phase I/II Study of Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia (ALL) or ALL in Relapse.
Phase of Trial: Phase I/II
Latest Information Update: 25 Jul 2012
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Acute lymphoblastic leukaemia
- Focus Therapeutic Use
- 25 Jul 2012 Actual end date (1 Jul 2011) added as reported by ClinicalTrials.gov.
- 15 Feb 2011 Planned End Date changed from 1 Jun 2012 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 15 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.